



ASX Announcement

31 May 2019

## Results of Annual General Meeting

**Creso Pharma Limited** (ASX:CPH, FRA:1X8) (the “Company” or “Creso”) today held its Annual General Meeting of Members at Quest Kings Park, 54 Kings Park Road, West Perth WA 6005.

All resolutions were passed on a show of hands.

In accordance with section 251AA of the Corporations Act 2001 (Cth), a summary of the proxy votes for each resolution is attached.

**Ends**

### Investor Enquiries

EverBlu Capital

E: [info@everblucapital.com](mailto:info@everblucapital.com)

P: +61 2 8249 0000

### About Creso Pharma

[www.cresopharma.com](http://www.cresopharma.com)

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.

It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

# Disclosure of Proxy Votes

## Creso Pharma Limited

Annual General Meeting

Friday, 31 May 2019



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
01 Adoption of Remuneration Report	S	16,515,736	15,172,678	498,602	148,029	844,456	n/a	n/a	n/a
02 Re-election of Director – Adam Blumenthal	S	37,203,946	36,175,655	210,694	159,820	817,597	n/a	n/a	n/a
03 Appointment of Auditor at AGM to fill vacancy	S	37,341,941	36,380,004	139,492	21,825	822,445	n/a	n/a	n/a
04 Re-adoption of Incentive Performance Rights Plan	S	16,386,563	15,123,419	433,807	277,202	829,337	n/a	n/a	n/a
05 Ratification of prior issue of Options to Lenders	S	37,193,725	35,948,743	396,197	170,041	848,785	n/a	n/a	n/a
06 Ratification of prior issue – Shares and Options	S	36,317,738	35,424,092	344,111	44,344	549,535	n/a	n/a	n/a
07 Selective Share Buy-Back	S	37,301,496	36,243,157	229,044	62,270	829,295	n/a	n/a	n/a
08 Approval of 10% Placement Capacity	S	37,329,647	35,810,869	646,243	34,119	872,535	n/a	n/a	n/a
09 Approval to issue Convertible Notes to Unrelated Parties	S	31,328,607	29,909,385	540,137	35,159	879,085	n/a	n/a	n/a

